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Probiotics are live microorganisms, and viability after transit through the gastrointestinal
tract (GIT) is considered an inherent property of the health benefits of probiotics. The aim
of the present study was to quantify the viable and total loads of Lactobacillus paracasei
DG cells after passage through the GIT following the consumption of the probiotic
product Enterolactis (L. casei DG R©; L. paracasei CNCM I-1572; L. paracasei DG) from
drinkable vials by healthy adults. We developed a novel method for discriminating and
enumerating culturable L. paracasei DG cells based on the unique sticky, filamentous
phenotype of this strain on MRS agar containing vancomycin and kanamycin. The
identity of DG was also confirmed with strain-specific primers by colony PCR. This
method was used for a recovery study of the DG strain to quantify viable cells in the
fecal samples of 20 volunteers during a 1-week probiotic consumption period and a 1-
week follow-up. We isolated L. paracasei DG from at least one fecal sample from all the
volunteers. The highest concentration of viable DG cells [ranging from 3.6 to 6.7 log10
colony-forming unit (CFU) per gram of feces] in the feces was observed between 4 and
8 days from the beginning of Enterolactis intake and for up to 5 days after cessation
of intake. As expected, the total DG count determined by real-time quantitative PCR
(qPCR) was mostly higher than the viable DG cells recovered. Viable count experiments,
carried out by combining ad hoc culture-based discriminative conditions and strain-
specific molecular biological protocols, unambiguously demonstrated that L. paracasei
DG can survive gastrointestinal transit in healthy adults when ingested as Enterolactis in
drinkable vials containing no less than one billion CFU at the end of shelf life.
Keywords: probiotic, Enterolactis, EPS, qPCR, isolation
INTRODUCTION
Probiotics are “live microorganisms that, when administered in adequate amounts, confer a health
benefit on the host” (Hill et al., 2014). Therefore, by definition, the term probiotic is restricted to live
microbial cells. According to the regulations of numerous countries, the actual number of microbial
colony-forming units (CFUs) in a probiotic product cannot be lower than the value indicated on
Frontiers in Microbiology | www.frontiersin.org 1 August 2018 | Volume 9 | Article 1720
fmicb-09-01720 July 30, 2018 Time: 19:29 # 2
Arioli et al. REVENANT-DG: L. paracasei DG Recovery Study
the label until the end of the shelf life of the product.
Consequently, both producers and competent public authorities
constantly assess the viable counts of commercial probiotic
products to ensure compliance with label specifications.
Simultaneously, many industrial efforts are being made to
identify strategies to keep bacterial cells viable during the
various production steps and in the final product until the
end of the shelf life; these strategies include the selection
of appropriate culture media, the use of protective agents
during the freeze-drying process, microencapsulation,
and improvements in packaging systems (da Cruz et al.,
2007; Savini et al., 2010; Goderska, 2012; Mai et al.,
2017).
Although microbial cell viability is constantly monitored
for each marketed probiotic product, only limited data are
available regarding the capacity of a particular microbial
strain in a specific probiotic formulation to survive in the
gastrointestinal tract (GIT) upon ingestion. Nonetheless, viability
is conventionally considered a prerequisite for the health benefit
of a probiotic, and accordingly, viable probiotics have been
demonstrated to be more effective than non-viable probiotics
for certain health-promoting activities (Lahtinen, 2012). In
this context, the first “FAO/WHO Expert Consultation on
Evaluation of Health and Nutritional Properties of Probiotics”
stated that the ability to remain viable at the target site
should be verified for each potential strain (FAO/WHO,
2001).
The conventional process of selecting novel potential probiotic
strains includes in vitro assessment of the ability of the
strains to survive at low pH, in simulated gastric juice or
in the presence of bile salts. However, in vivo assessment of
probiotic viability is a more challenging task, possibly due to
the difficulties associated with setting up intervention trials
with human volunteers and because of technical limitations.
The use of human biopsies is an impractical option, and
therefore, the ability of probiotic microorganisms to survive
in the GIT is assessed by analyzing fecal samples. However,
conventional selective and/or discriminative growth media
can barely distinguish a specific probiotic strain from other
members of closely related taxa that are naturally present in
the sample. The development of molecular approaches based
on strain-specific primer design may solve the problem of
selectivity, although PCR protocols may lack sensitivity and, most
importantly, will not permit assessment of the viability of the
probiotic cells. For these reasons, culture-based methods have
been combined with molecular approaches to obtain adequate
sensitivity and specificity (Dommels et al., 2009; Poutsiaka
et al., 2017). Nevertheless, in vivo assessment of the ability to
survive gastrointestinal transit has been carried out so far for
only a limited number of well-known commercial probiotics
(Verna and Lucak, 2010; Derrien and van Hylckama Vlieg,
2015).
Lactobacillus paracasei CNCM I-1572 (commercially
known as L. casei DG R©; L. paracasei DG) is a bacterial strain
commercially available as part of the Enterolactis R© product
line. Enterolactis is currently the best-selling probiotic food
supplement in Italy, which is the country with the largest
probiotic market in the world. L. paracasei DG has been
demonstrated to possess the ability to modulate the intestinal
microbial ecosystems of healthy adults (Ferrario et al., 2014)
and to influence host immune response (Balzaretti et al.,
2015; Cremon et al., 2017) via its unique polysaccharide
capsule (Balzaretti et al., 2017). L. paracasei DG has also
been demonstrated to possess therapeutic potential for
several dysfunctions and pathological conditions such as
ulcerative colitis (D’Incà et al., 2011), diverticular disease
(Tursi et al., 2013; Turco et al., 2017), small intestinal
bacterial overgrowth (Rosania et al., 2013), and irritable
bowel syndrome (Compare et al., 2017; Cremon et al.,
2017).
In this study, we present the development of a strategy that
combines culture-based methods and molecular methods for
strain-specific selective enumeration of viable L. paracasei DG
cells in fecal samples. Subsequently, we adopted this protocol
to demonstrate the ability of L. paracasei DG to survive
gastrointestinal transit when consumed by healthy adults via a
probiotic formulation consisting of at least one billion bacterial
CFU in a 10-ml suspension.
MATERIALS AND METHODS
Bacterial Strain and Selective Medium
Lactobacillus paracasei DG (CNCM I-1572) was routinely
cultivated anaerobically at 37◦C for 24 h in MRS broth
or in vk-MRS agar (Difco Laboratories Inc., Detroit, MI,
United States) supplemented with 1 µg/ml vancomycin and
10 µg/ml kanamycin (Sigma-Aldrich, Steinheim, Germany).
The culturable bacterial content per vial used for the study
was determined by resuspending at least 5 g of freeze-dried
L. paracasei DG biomass in maximum recovery diluent (MRD)
(Scharlab, Milan, Italy); then, this initial cell suspension
was homogenized in a sterile Stomacher bag by using a
Colworth Stomacher 400 instrument (Seward, West Sussex,
United Kingdom) for 3 min. Serial 10-fold dilutions were
prepared in MRD, and total microorganismal content
was determined by the spread plate technique on vk-MRS
agar.
Human Intervention Study Methods
Study title: recovery study with L. casei DG R© (Enterolactis R©) in
drinkable vials in healthy adult volunteers (REVENANT-DG).
Study design: open-label pilot microbiological study (Figure 1).
FIGURE 1 | Design of the study. Vertical arrows indicate the day of collection
of the fecal sample (when available) from the volunteer.
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Number of participants: 20 volunteers (Table 1). Study population:
healthy (non-diseased) adult volunteers of both sexes, aged
18–55 years, who provided signed informed consent of their
participation in the study. Exclusion criteria were as follows: (i)
antibiotic consumption in the month preceding the start of the
trial; (ii) consumption of antacids or prokinetic gastrointestinal
drugs; (iii) chronic inflammatory bowel diseases; (iv) intestinal
diseases of infectious origin; (v) episodes of viral or bacterial
enteritis in the 2 months prior to the study; (vi) episodes
of gastric or duodenal ulcers in the previous 5 years; (vii)
pregnancy or breast-feeding; (viii) recent history of alcohol
abuse or suspected drug use; and (ix) any severe disease
that may interfere with treatment. Probiotic formulation under
study: Enterolactis R© (Sofar, Trezzano Rosa, Italy) in drinkable
vials, which consisted of a plastic vial containing 10 ml
of 2% fructose solution (additives: citric acid as an acidity
controller, and sodium benzoate and potassium benzoate as
preservatives) and a plastic/aluminum push-button cap (DryCap
technology) containing at least one billion CFU/vial of freeze-
dried L. paracasei DG biomass. Study protocol: during the initial
visit, each volunteer provided signed informed consent and
was trained on the entire procedure; then, the study consisted
of a pre-recruitment phase (run-in, 1 week), during which
the volunteers followed their conventional diet with a ban
on probiotic-fermented milks (traditional yogurt was allowed
during this phase) and probiotic, prebiotic and symbiotic foods
and supplements. At the end of this period, the volunteers
were invited to consume one drinkable vial of Enterolactis per
day for 1 week. The product was consumed on an empty
stomach in the morning, at least 10 min before breakfast, or,
if forgotten, in the evening, before bedtime and at least 2 h
TABLE 1 | Basic characteristics of study participants.
Subject Sex Age
(n = 20) (8F/12M) (22–53 years)
S01 M 53
S02 F 46
S03 F 47
S04 F 27
S05 F 27
S06 F 28
S07 M 25
S08 F 23
S09 M 23
S10 F 27
S11 M 24
S12 M 28
S13 F 31
S14 M 31
S15 M 31
S16 F 26
S17 M 26
S18 F 26
S19 F 42
S20 M 22
after the last meal. Following the 7 days of administration, the
volunteers underwent a 1-week follow-up, which was identical
to the period of pre-recruitment. Sample collection: at the
beginning of the study, the volunteers were trained to collect
and deliver the fecal samples as follows: each stool specimen
(at least 2 g) was collected in special sterile containers, stored
at room temperature, and delivered to the laboratory within
24 h. Preliminary experiments demonstrated that strain DG
can survive in human feces at room temperature and 37◦C at
least 48 h without significant decrease of the viable count (not
shown). To verify the ability of the DG strain to survive passage
through the GIT, the fecal samples collected were immediately
subjected to viable bacterial counts. To obtain fecal bacterial
counts, 1-g fecal samples were diluted in MRD, homogenized
in a sterile Stomacher bag, plated on vk-MRS and incubated
anaerobically at 37◦C for 48 h. Throughout the study period, the
frequency and consistency of the stools were evaluated according
to a validated fecal scoring system (Bristol stool scale). Ethical
statement: the study protocol was approved by the Research
Ethics Committee of the Università degli Studi di Milano
(opinion no. 37/16, 15th December 2016). Written informed
consent was obtained from all the subjects before recruitment.
Volunteer compliance: volunteer compliance, as determined by
verbal assessment, was almost 100%. All programmed fecal
samples were delivered by volunteers, with the only exception of
subject S1, we voluntarily interrupted fecal sample collections at
day 12.
DNA Extraction
After microbiological analysis, the fecal samples were stored
at −80◦C until DNA extraction. Samples collected from each
subject on different days (n = 9; T0–T8) were thawed on
ice and mixed vigorously for 2–3 min with a sterile spatula;
then, 250 mg of each sample was weighed and processed
with a DNeasy R© PowerLyzer R© PowerSoil R© Kit (Qiagen, Hilden,
Germany) with the following modifications: tubes containing
samples were incubated at 65◦C for 10 min after addition
of solution C1. Before extraction, mechanical lysis of the
cells was carried out using a Precellys 24 bead homogenizer
(Bertin Technologies, Montigny le Bretonneux, France). Then,
the extraction was conducted according to the manufacturer’s
specifications. The DNA extracted from fecal samples was
quantified by using a NanoDrop (BioTek Instruments, Inc., CA,
United States). Finally, the DNA was stored at −80◦C until
molecular analysis.
L. paracasei DG Quantification by qPCR
Real-time quantitative PCR (qPCR) protocols were adopted for
the quantification of L. paracasei DG in fecal metagenomic
DNA, targeting the glycosyl transferase gene welF with the
primers rtWELFf (5′-TACTAAAGAAATTAGCTTTTGT-3′) and
rtWELFr (5′-AGTAATGTCTGCATCCTCCA-3′) (Ferrario et al.,
2014) in a final volume of 15 µl containing 7.5 µl of EvaGreen R©
Supermix (Bio-Rad Laboratories, Segrate, Italy) and 0.5 µM
of each primer; 50 ng of template DNA samples was used
in each reaction. The amplification was carried out using the
following thermal program: initial hold at 95◦C for 3 min
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followed by 39 cycles of 95◦C for 30 s, 58◦C for 30 s, and
72◦C for 30 s. A standard calibration curve for the absolute
quantification of the total number of L. casei DG R© was prepared
by mixing five different fecal samples (of varying consistency)
that were collected before the consumption of probiotics.
Different numbers of L. casei DG R© cells (n = 10; 1–1× 109) were
added to 250-mg fecal samples; one fecal sample was used as a
control (without the addition of bacterial cells). All the samples
were subjected to DNA extraction as mentioned above. The
standard curve was obtained by plotting the average Cq values
versus log10 of the number of cells added to each fecal sample.
Melting curves were analyzed with Bio-Rad CFX Manager
3.1 software to confirm the specificity of the amplification
products.
Colony PCR for Identification of
L. paracasei DG Colonies
To confirm the identities of the DG colonies, we carried
out end-point colony PCR by randomly selecting colonies
with sticky, filamentous phenotypes. Colonies with different
phenotypes were always included as negative controls. PCRs
were performed in 25-µl reaction mixtures, each containing
one colony (picked with a sterile wooden stick), 2.5 µl of
10× reaction buffer, 200 µmol/l of each dNTP, 0.5 mmol/l
MgCl2, 0.5 µmol/l each primer (rtWELFf and rtWELFr), and
0.5 U DreamTaqTM DNA polymerase (Thermo Fisher Scientific
Inc., Monza, Italy). Amplifications were carried out using a
Mastercycler 96 (Eppendorf, Milan, Italy). The PCR mixtures
were subjected to the following thermal cycling conditions:
initial hold at 95◦C for 3 min followed by 39 cycles of 95◦C
for 30 s, 58◦C for 30 s, and 72◦C for 30 s. Amplification
products were resolved by electrophoresis on a 2% (w/v)
agarose gel (with 0.2 µg/ml ethidium bromide) in 1× TAE
buffer (40 mmol/l Tris-acetate, 1 mmol/l EDTA, pH 8.0) and
photographed. A 1-kb GeneRuler DNA Ladder Mix was used as
a size marker.
RESULTS
Development of a Method for the
Enumeration of Live L. paracasei DG
Cells
To develop culture conditions for selective and discriminative
growth of L. paracasei DG, we implemented the cultivation
protocol suggested by the Italian Higher Institute of Health
(ISS) for the enumeration of heterofermentative lactobacilli in
probiotic products (ISSN 1123-3117 ISTISAN 08/36; available at
http://www.iss.it/binary/publ/cont/08-36_web.1229959899.pdf
as accessed on February 10th, 2018). The ISSN protocol suggested
the use of 1 µg/ml vancomycin for the selective counting of
heterofermentative lactobacilli; however, during the preliminary
experiment, the use of such a medium allowed the growth of
many non-DG colonies, which hampered the identification and
counting of the probiotic strain under investigation. For this
reason, based on the antibiotic resistance profile of L. paracasei
TABLE 2 | Minimum inhibitory concentrations (MICs) of Lactobacillus paracasei
DG and the EFSA reference strain L. paracasei LMG 12586 determined via a
microdilution assay.
Antibiotic molecule ISO10932
(µg/ml)∗
MIC (µg/ml)
LMG 12586
MIC (µg/ml)
L. paracasei
DG
Ampicillin 0.5–2 1 1
Vancomycin Not required >16 >16
Gentamycin 1–4 4 4
Kanamycin 16–64 32 256
Streptomycin 8–32 16 32
Erythromycin 0.062–0.25 0.125 0.125
Clindamycin 0.062–0.25 0.125 0.125
Tetracycline 1–4 2 8
Chloramphenicol 4–8 4 4
The results are compared with cutoff values defined by EFSA (∗) for the purpose of
distinguishing resistant strains from susceptible strains within the taxonomic group
Lactobacillus casei/paracasei (European Food Safety Authority [EFSA], 2012).
DG (Table 2), we also added 10 µg/ml kanamycin to the medium
(vk-MRS medium), which resulted in an evident decrease
in the background without affecting the growth of the DG
strain compared to the growth of this strain in normal MRS
medium or MRS supplemented with the only vancomycin.
The use of higher concentrations of the antibiotics resulted in
reduced viable count of the DG strain. In addition, we observed
that the DG colonies on vk-MRS agar had a peculiar sticky,
filamentous phenotype, allowing the discrimination of this
strain from the colonies of closely related lactobacilli, which
typically have a creamy consistency (Figure 2 and Supplementary
File S1).
Finally, to unambiguously confirm that the colonies isolated
on the vk-MRS plates belonged to the DG strain, we performed
end-point colony PCR analysis with strain-specific primers on
randomly selected colonies. The results confirmed that only those
colonies with the sticky, filamentous phenotype belonged to
L. paracasei DG. This method allowed us to precisely distinguish
the DG colonies from the other fecal microorganisms and to
selectively count colonies of the probiotic strain under study.
Viable Counts of L. paracasei DG in the
Fecal Samples of Healthy Adults
We used the protocol based on vk-MRS medium combined
with strain-specific PCR of the isolated colonies to determine
viable counts of L. paracasei DG in the fecal samples of
20 adult volunteers over 1 week of probiotic intake and
during a 1-week follow-up. Subject compliance was excellent,
and all 20 subjects completed the study. Moreover, no
adverse events were recorded for the entire duration of the
probiotic treatment. Based on the results of strain-specific PCR
(Supplementary Figure S1), 100% of the analyzed colonies with
sticky, filamentous phenotypes belonged to L. paracasei DG,
confirming that vk-MRS is a suitable medium for the selective
counting of this strain. Notably, although we found wide inter-
individual variability, we isolated L. paracasei DG from at
least one fecal sample from all 20 volunteers, demonstrating
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FIGURE 2 | Sticky, filamentous consistency of the colonies of Lactobacillus
paracasei DG grown on vk-MRS agar plates.
that this probiotic bacterium can survive gastrointestinal
transit when consumed via the formulation Enterolactis in
drinkable vials. Overall, we found the highest concentration
of viable L. paracasei DG in the fecal samples obtained
between 4 and 8 days after the beginning of Enterolactis
intake. The highest concentration of DG isolated from a
single subject ranged between 3.6 and 6.7 log10 CFU per
gram of feces (mean of 6.1 log10 CFU/g). In particular,
we observed profound inter-subject variability in terms of
kinetics of persistence. In fact, while from some subjects
(e.g., S1) DG cells were retrieved from the first evacuation
after intake of the probiotic product, from others (e.g., S2
and S9), viable DG cells were isolated only after the end
of the 1-week probiotic intake period (Figure 3). In general,
however, viable DG cells were isolated from the feces of the
volunteers until 5 days after the cessation of Enterolactis intake
(Figure 3).
Total L. paracasei DG Counts in the Fecal
Samples of Healthy Adults
The fecal samples collected during the 2-week trial were also used
for the quantification of total L. paracasei DG cells by means
of qPCR with strain-specific primers. As expected, the total DG
counts determined via qPCR were mostly higher than the viable
DG counts (Figure 3). Accordingly, the highest concentration
of DG cells isolated from each subject, as calculated by qPCR,
ranged between 5.4 and 7.6 log10 cells per gram of feces (mean
of 7.1 log10 cells/g). However, while some subjects exhibited very
similar total and viable counts (e.g., S1, S15, S17, and S20), others
exhibited total counts that far exceeded viable counts in terms
of both cell concentration and persistence (e.g., S2, S5, and S19;
Figure 3). Overall, while the recovery of culturable DG cells was
possible for up to 5 days after the intake period, the detection of
DG cells by qPCR was possible for up to 7 days on average.
Bowel Habits and DG Recovery
The Bristol Stool Chart did not reveal any significant alteration in
bowel habits, and no gastrointestinal abnormalities were reported
by the volunteers during the entire study. Although intestinal
transit time and bowel habits could plausibly determine the
differences observed among the different volunteers, the data
regarding fecal types and evacuations per day did not correlate
with the results of viable or total DG recovery (Supplementary
Figure S2).
DISCUSSION
Survival of gastrointestinal transit has been listed among the
criteria that a microorganism should fulfill to qualify as a
probiotic (Borchers et al., 2009; Verna and Lucak, 2010).
Studies of probiotic viability in humans after ingestion mostly
rely on quantification in feces and are also referred to as
“persistence” or “recovery” studies. The viable recovery of
probiotics from feces is technically challenging because feces are
microbiologically very complex, hosting thousands of different
microbial species. Furthermore, probiotics mostly belong to
the genera Lactobacillus and Bifidobacterium, which naturally
inhabit the human gut and can, therefore, be co-isolated with
the probiotic strain of interest. Reportedly, antibiotics and
colony morphology have been used to address this challenge
and facilitate the selective identification of colonies belonging to
specific strains under study (Larsen et al., 2006; Mai et al., 2017;
Poutsiaka et al., 2017). In addition, more reliable results have
been obtained when molecular approaches have been combined
with conventional isolation on agar plates. For instance, Tuohy
et al. (2007) enumerated the L. paracasei strain Shirota using
lactitol-LBS-vancomycin agar combined with pulsed-field gel
electrophoresis to confirm colony identity. In another study, the
Shirota strain was selectively quantified in feces using lactitol-
lactobacillus selection-vancomycin agar plates with ELISA for
confirmation of colony identity (Wang et al., 2015). Furthermore,
fluorescent whole-cell hybridization was used to identify colonies
of Bifidobacterium animalis subsp. lactis BB-12-like colonies
grown on MRS agar supplemented with cysteine-HCl and
tetracycline (Larsen et al., 2006). Molecular fingerprinting (rep-
PCR, RAPD-PCR, or AP-PCR) of colonies isolated from feces has
also been used to confirm strain identity (Songisepp et al., 2005;
Prilassnig et al., 2007; Verdenelli et al., 2009; Pino et al., 2017).
Here, we designed an effective and reliable protocol for the
selective enumeration of viable cells of L. paracasei DG in human
feces via the exploitation of the exopolysaccharide (EPS) capsule
of this bacterium (DG EPS) (Balzaretti et al., 2017). According
to the analysis of the complete genome (chromosome and
plasmids), L. paracasei DG does not have any antibiotic resistance
genes (Balzaretti et al., 2015), and therefore, the modestly
increased ability of the DG strain to resist certain antibiotics
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FIGURE 3 | Viable (black lines and circles) and total (blue lines and squares) counts of Lactobacillus paracasei DG in the fecal samples of healthy adult volunteers
who ingested Enterolactis in drinkable vials once daily. (A) Data per subject; (B) mean data (n = 20). Open symbols refer to fecal samples collected during the week
of probiotic intervention.
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can be reasonably explained by the existence of the EPS capsule,
which may partially impede antibiotic penetration into the cell.
In addition, many strains of lactobacilli have been reported to
have high natural resistance to aminoglycosides (e.g., gentamicin
and kanamycin). We exploited the observed modest resistance
of strain DG to certain antibiotics, which is intrinsic and is not
associated with horizontally transmissible genetic elements, by
adding the antibiotics vancomycin and kanamycin to the medium
developed in this study to enumerate the DG strain. In addition,
the DG EPS imparts a sticky, filamentous texture to the colonies,
allowing easy discrimination of DG from other lactobacilli.
Finally, the genetic region encoding the DG EPS has a unique
DNA sequence (Balzaretti et al., 2017), therefore, permitting the
design of strain-specific primers (Balzaretti et al., 2015). All the
colonies with the sticky, filamentous phenotype detected on the
plates were demonstrated by colony PCR with strain-specific
primers as belonging to the DG strain, demonstrating that the
developed protocol is suitable for the selective enumeration of
strain DG.
Apparently, the literature contains contradictory reports
regarding the ability of probiotic microorganisms to survive
gastrointestinal transit. Previous studies, in fact, have
demonstrated that the recovery of live cells of probiotic
microorganisms after gastrointestinal transit in humans is poor
(Hamilton-Miller et al., 1999; Temmerman et al., 2003). In a
subsequent study, out of six different commercially available
products, only Escherichia coli Nissle 1917 and Enterococcus
faecium SF 68 were consistently detected in human feces,
whereas ingested bifidobacteria and lactobacilli (including a
L. paracasei strain) were not recovered from stool (Prilassnig
et al., 2007). A higher number of studies, however, have reported
the successful recovery of different probiotics from human
feces after ingestion (Verdenelli et al., 2009; Derrien and van
Hylckama Vlieg, 2015). Overall, the results are inconclusive,
primarily because the recovery of probiotics from human feces
depends on several pivotal factors: (i) the dose of the ingested
live microbial cells; (ii) the intrinsic ability of the microorganism
to resist chemical and physical stresses in the stomach and gut
(e.g., acidity and bile salts); and (iii) the product composition
in terms of excipients and/or ingredients. Accordingly, for
instance, Lactobacillus fermentum ME-3 was retrieved from the
feces of all volunteers (n = 16) who received the probiotic as
fermented goat milk but not from volunteers who ingested the
probiotic cells as gelatin-coated capsules (n = 12) (Songisepp
et al., 2005). The results of another study showed that, compared
to capsules and yogurt, cheese negatively influenced the fecal
quantity of Propionibacterium freudenreichii subsp. shermanii
JS and B. animalis subsp. lactis BB12 in human feces, whereas
Lactobacillus rhamnosus GG and LC705 were not affected by
the matrix (Saxelin et al., 2010). Therefore, intestinal recovery
should be investigated for specific probiotic strains in precise
product formulations. Nonetheless, reliable studies have been
carried out only for a few well-known commercially available
probiotics, such as L. paracasei Shirota, L. rhamnosus GG,
and B. animalis subsp. lactis BB12. For instance, Wang et al.
isolated viable cells of the Shirota strain from the feces of all
volunteers (n = 25) after 7- and 14-day periods of consumption
of a milk-based probiotic beverage (corresponding to a daily
intake of approximately 10 billion CFU); however, the Shirota
strain was detected in the feces of only three subjects (out of 25)
7 days after cessation of product ingestion (Wang et al., 2015).
In another study, the Shirota strain was retrieved from the feces
collected from 9 healthy adult volunteers after 7, 14, and 21 days
of daily consumption of a fermented milk drink, corresponding
to a total intake of approximately 50 billion CFU per day; 7 days
after cessation of fermented milk intake, the Shirota strain was
still isolated from the feces of six subjects, albeit at a much lower
concentration (Tuohy et al., 2007). The longer persistence of the
probiotic in a subgroup of volunteers observed in the study by
Tuohy et al. (2007) than that in the REVENANT-DG trial was
possibly due to the longer treatment (3 weeks) and much higher
total daily intake of probiotic cells (50 billions) in the study by
Tuohy et al. (2007).
More recently, the well-known probiotic strains B. animalis
subsp. lactis BB12 and L. rhamnosus GG were successfully
recovered alive from the stools of 16 out of 19 healthy volunteers
who each ingested both strains together at a quantity of one
billion CFU per day for 3 weeks as a powder in a sachet; the
quantitative culture-based experiment, however, failed to isolate
strain BB12 or GG 28 days after the end of the supplementation
period (Poutsiaka et al., 2017). L. rhamnosus GG and B. animalis
subsp. lactis BB-12, in particular, have been retrieved from the
feces of healthy subjects and patients when administered with
a variety of formulations, including different pharmaceutical
forms and foods (Larsen et al., 2006; Ahlroos and Tynkkynen,
2009; Dommels et al., 2009; Saxelin et al., 2010; Granata et al.,
2013). Nonetheless, this information is not available for most
commercially available probiotics.
In our study, we examined the recovery of live L. paracasei
DG from the GITs of healthy individuals after oral ingestion
of Enterolactis, a probiotic supplement consisting of at least
one billion CFU per dose of bacterial cells, suspended in a 10-
ml fructose solution in drinkable vials. The intervention lasted
only 1 week and was based on the intake of a single one-
billion-CFU dose of probiotic cells per day; nonetheless, the
intervention was effective enough to lead to the recovery of viable
L. paracasei DG from all 20 volunteers enrolled in the study,
clearly demonstrating that the Enterolactis in drinkable vials,
containing at least one billion CFU, is suitable for successful
delivery of probiotic cells to the human intestine.
The abovementioned studies demonstrated that the
colonization of the human intestinal tract by an ingested
probiotic microorganism is transient, and after the cessation of
ingestion, the probiotic rapidly approaches the detection limit
via kinetic mechanisms that possibly depend on the dose of
the administered microbial cells. In particular, the results of
our study on L. paracasei DG are consistent with the literature
regarding the L. paracasei Shirota strain, the persistence of which
in the guts of healthy adults was demonstrated to disappear
within 1 week after cessation of probiotic intake (Tuohy et al.,
2007; Wang et al., 2015).
In this study, we invited volunteers to ingest the probiotic on
an empty stomach, at least 15 min before breakfast. There is no
convincing information in the scientific literature to answer the
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question of whether probiotics should be taken with food or on
an empty stomach. However, this factor could affect microbial
survival in the stomach and intestine upon ingestion, and future
investigations on the topic are warranted.
In conclusion, in this report, we presented the results of a
comprehensive recovery study of the probiotic strain L. paracasei
DG. Viable count experiments carried out by combining ad hoc
culture-selective/discriminative conditions and strain-specific
molecular biological protocols unambiguously demonstrated
that L. paracasei DG can survive gastrointestinal transit in
healthy adults when ingested as Enterolactis in drinkable vials,
a formulation consisting of a 10-ml drinkable suspension
containing no less than one billion CFU. Recovery studies to
assess microbial viability after gastrointestinal transit should be
a mandatory step in the characterization process of any probiotic
product. Our study shows that reliable verification of microbial
survival in feces can be performed in a rigorously strain-specific
manner by developing enumeration protocols for viable cells
based on the specific genetic and phenotypic characteristics of
probiotic microorganisms of interest.
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